Flag of the European Union EU Clinical Trials Register Help

Clinical trials for White blood cell differential

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: White blood cell differential. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-003276-39 Sponsor Protocol Number: 09072012 Start Date*: 2013-01-09
    Sponsor Name:Hæmatologisk afdeling, Roskilde Sygehus, Region Sjælland
    Full Title: Investigation of the value of Iron and Bonemarrow stimulation in differential diagnostic of Polycythemia Vera and Essential Thrombocytosis
    Medical condition: Polycythemia Vera Essential thrombocytosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10022958 Iron and trace metal metabolism disorders HLGT
    15.0 10005329 - Blood and lymphatic system disorders 10029355 Neutropenias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002872-41 Sponsor Protocol Number: ELR100710 Start Date*: 2005-10-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis
    Medical condition: Seasonal allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002379-40 Sponsor Protocol Number: CAFQ056B2278 Start Date*: 2012-01-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003360-39 Sponsor Protocol Number: BMS_IM101-631 Start Date*: 2017-06-27
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis
    Medical condition: Steroid-refractory Sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005772-16 Sponsor Protocol Number: HEH-SF-01 Start Date*: 2016-06-22
    Sponsor Name:Department of Surgery, Herlev Hospital
    Full Title: The safety and pharmacokinetics of intraperitoneal administration of granulocyte-macrophage colony-stimulating factor, fosfomycin, and metronidazole in patients undergoing appendectomy for uncompli...
    Medical condition: We intend to investigate the safety of treating secondary infectious peritonitis due to uncomplicated appendicitis with intraperitoneally administered fosfomycin, metronidazole and GM-CSF.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10000677 Acute appendicitis LLT
    19.0 100000004848 10053349 Pharmacokinetic study LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000533-39 Sponsor Protocol Number: CAIN457A2302E1 Start Date*: 2012-06-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subj...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed) LV (Completed) SE (Completed) LT (Completed) ES (Completed) BE (Completed) EE (Completed) GB (Completed) DE (Completed) FI (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001648-12 Sponsor Protocol Number: OVG2015/02 Start Date*: 2015-09-03
    Sponsor Name:University of Oxford
    Full Title: A phase II, open label trial to describe immune and transcriptional responses to MF59 adjuvanted trivalent influenza vaccine (ATIV) in 13-24 month healthy children and adults 18-65 years
    Medical condition: This trial is investigating healthy children and adult's gene expression and immune response to the Fluad (MF59)-adjuvanted trivalent influenza vaccine and also comparing these to the local and gen...
    Disease:
    Population Age: Infants and toddlers, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022150-16 Sponsor Protocol Number: Moxifloxacin Sepsis PEG Start Date*: 2011-01-27
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik f.klinische Pharmakologie
    Full Title: Determination of Moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients including a pilot phase
    Medical condition: To evaluate feasibility of Moxifloxacin determination in septic patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003300-31 Sponsor Protocol Number: 20159460(c) Start Date*: 2017-06-13
    Sponsor Name:Hellenic Society for the Study of Bone Metabolism
    Full Title: Evaluation of the efficacy of Denosumab in adult patients with Langerhans Cell Histiocytosis (LCH) : a multiple-site, single arm, open label Clinical Trial.
    Medical condition: Langerhans Cell Histiocytosis (LCH) is a rare disease of unknown etiology with variable clinical course exhibiting both neoplastic and inflammatory features. It is characterized by the accumulatio...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069698 Langerhans' cell histiocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001929-40 Sponsor Protocol Number: AZT_DSTB_BB Start Date*: 2017-11-21
    Sponsor Name:University Medical Center Groningen
    Full Title: A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis
    Medical condition: Pulmonary tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037440 Pulmonary tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024042-30 Sponsor Protocol Number: DUR001-301 Start Date*: 2012-05-04
    Sponsor Name:Durata Therapeutics, Inc
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SKI...
    Medical condition: acute bacterial skin and skin structure infections (abSSSI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005830-63 Sponsor Protocol Number: 0485-CL-0004 Start Date*: 2009-10-30
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002539-14 Sponsor Protocol Number: ANB020-002 Start Date*: 2016-12-13
    Sponsor Name:AnaptysBio Inc
    Full Title: Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002130-40 Sponsor Protocol Number: DUR001-302 Start Date*: 2011-11-23
    Sponsor Name:Durata Therapeutics, Inc
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SK...
    Medical condition: acute bacterial skin and skin structure infections (abSSSI)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) HU (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000419-15 Sponsor Protocol Number: DUR001-303 Start Date*: 2014-07-28
    Sponsor Name:Durata Therapeutics International B.V.
    Full Title: A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin ...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005116-28 Sponsor Protocol Number: 38495 Start Date*: 2012-09-10
    Sponsor Name:
    Full Title: A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment. The ReCab trial
    Medical condition: Metastatic prostate cancer/bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004636-52 Sponsor Protocol Number: 2005AN005 Start Date*: 2006-02-20
    Sponsor Name:Heart of England NHS Foundation Trust
    Full Title: Randomised Double-Blind Placebo Controlled Trial of 40mg/day of Atorvastatin on Reduction in Severity of Sepsis in Ward Patients
    Medical condition: Sepsis is the clinical syndrome defined by the presence of both infection and a systemic inflammatory response. Sepsis is common in general medical and surgical wards with an estimated prevalence ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000924-11 Sponsor Protocol Number: CTCL Start Date*: 2015-06-17
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor
    Full Title: Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.
    Medical condition: Cutaneous T cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003044-20 Sponsor Protocol Number: CASK0117 Start Date*: 2017-11-27
    Sponsor Name:Cassella-med GmbH & Co. KG
    Full Title: A Randomised, Double-blind, Placebo-controlled, Multi-centre Clinical Study to Investigate the Efficacy and Safety of Three Doses of Cineole in Subjects with Severe Acute Bronchitis with or without...
    Medical condition: Severe acute bronchitis with or without associated common cold
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10000687 Acute bronchitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001729-28 Sponsor Protocol Number: IPI-145-03 Start Date*: 2012-07-17
    Sponsor Name: Infinity Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Cross-Over, Efficacy and Safety Study of IPI-145 in Mild Asthmatic Subjects Undergoing Allergen Challenge
    Medical condition: Mild asthma with allergen challenge
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003561 Asthma, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 14:03:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA